Evidence map›Paper›PMID 26223194›Full record

ArticleEndocrine pathology2015

MYC Analysis by Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA): a Series of Four Cases.

Kristine M Cornejo, Lloyd Hutchinson, Maryann St Cyr, Vania Nose, Patrick J McLaughlin, A John Iafrate, Peter M Sadow

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. A Rare Case of Primary Adrenal Epithelioid Angiosarcoma.The American journal of case reports · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Kristine M CornejoDepartment of Pathology, UMass Memorial Healthcare-University of Massachusetts Medical School, One Innovation Drive, Biotech 3, Worcester, MA, 01605, USA. Kristine.Cornejo@umassmemorial.org.
Lloyd HutchinsonDepartment of Pathology, UMass Memorial Healthcare-University of Massachusetts Medical School, One Innovation Drive, Biotech 3, Worcester, MA, 01605, USA.
Maryann St CyrDepartment of Pathology, UMass Memorial Healthcare-University of Massachusetts Medical School, One Innovation Drive, Biotech 3, Worcester, MA, 01605, USA.
Vania NoseDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Patrick J McLaughlinDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Peter M SadowDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USMassachusetts General Hospital · USUniversity of Massachusetts Chan Medical School · USUMass Memorial Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary adrenal angiosarcomas (PAA) are rare with 36 cases reported in the English literature. MYC protein expression and gene amplification have been detected in secondary angiosarcoma (AS), and a subset of primary AS. The aim of this study was to report the clinicopathologic features of PAA and examine these tumors for MYC amplification and protein expression in a small series of four cases (resection, n = 4). Three had available material for ancillary studies and were investigated for MYC gene abnormalities and protein expression using fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. Tumors occurred in three females and one male with a mean age of 69 (53-75) years. The sizes ranged from 8.5 to 15 (mean 11.5) cm and were epithelioid in morphology. All tumors had prominent necrosis, and the mitotic count ranged from 4 to 41/10 high-power fields (HPFs) (mean 20/10 HPFs, ×400). Immunohistochemically, the tumor cells were positive for CD31 in 4/4 cases, CD34 in 1/4 cases, and cytokeratin in 4/4 cases. The mean follow-up period was 10.8 (3-19) months, of which three patients died of disease with distant metastases, and one patient was alive with disease. MYC nuclear staining was identified in the three cases tested. Two cases showed polysomy of chromosome 8 without MYC amplification or rearrangement. Two MYC-positive cases by IHC demonstrated copy number gain in chromosome 8, and one MYC-positive case was not associated with a chromosome 8/MYC gene abnormality. In the context of new targeted therapies, MYC positivity in PAA may be clinically valuable in treating patients with these aggressive neoplasms.

Indexed as

Adrenal Gland NeoplasmsHemangiosarcomaProto-Oncogene Proteins c-mycAgedFatal OutcomeFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMiddle AgedMYC protein, humanProto-Oncogene Proteins c-mycAdrenalFISHImmunohistochemistryMYCPolysomyPrimary angiosarcoma

Identifiers

PMID26223194
OpenAlexW1001689738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.